Answers are grounded in this paper and cite their sources.
Meta-analysis shows chemo-free therapy improves safety and efficacy outcomes in HER2-positive breast cancer, indicating treatment benefits.
Objectives: Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is rapidly growing with poor outcomes if left untreated. Research evidence indicates that chemotherapy-free regimens can improve outcomes of HER2-positive early breast cancer while maintaining high oncogenic safety. The main objective of our study was to examine the efficacy and safety of chemotherapy-free regimens in patients with HER2-positive early breast cancer. Methods: A systematic literature search was conducted using the PubMed, CENTRAL, Google Scholar, and Embase databases to identify relevant randomized trials published until July 2024. Results: Five randomized trials, including 1489 patients with early-stage HER2-positive breast cancer, met the inclusion criteria for this meta-analysis. The pooled results showed that about 26.1% (182/698) of patients receiving chemo-free therapies achieve pathologic complete response (pCR). However, the subgroup analysis revealed that patients treated with trastuzumab plus pertuzumab and those treated with HER2-directed drugs plus endocrine therapy had significantly inferior pCR than those receiving chemotherapy combined with anti-HER2 drugs (OR: 0.22, P =0.0002 and OR: 0.25, P <0.00001). The meta-analytic results also demonstrated that patients receiving chemo-free therapies have high 3-year and 5-year invasive disease-free survival (iDFS) (95.40% and 85.71%) and 5-year event-free survival (EFS) (81.13). Regarding safety, the pooled results revealed that the discontinuation rates due to adverse events were statistically similar between the 2 groups (OR: 0.29, P =0.18). Conclusions: Chemotherapy-free regimens demonstrate promising responses and survival outcomes in patients with HER2-positive early breast cancer. However, the combination of anti-HER2 drugs with chemotherapy still demonstrates superior overall clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: